Our motto - 'bench to bedside' Till date, we have identified multi-omic signatures including genomic, epigenomic, and transcriptomic leads associated with the risk of complex disorders like gastric cancer, oropharyngeal cancer, oral cancer, and pre-term birth.  Now we are moving ahead to functionally validate these findings and translate them into meaningful therapeutic measures.